Abstract
Cytochrome P450, family 2, subfamily W, polypeptide 1 (CYP2W1) is a newly identified monooxygenase enzyme that is expressed specifically in tumor tissues and during fetal life. Particularly, high expression of CYP2W1 was observed in up to 60% of colorectal cancers and its expression correlated with poor survival. CYP2W1 has been shown to metabolize various endogenous substrates including lysophospholipids and several procarcinogens, such as polycyclic aromatic hydrocarbon. The specific substrate for CYP2W1, however, is currently unknown. Due to its tumor-specific expression and its unique catalytic activities in colorectal cancers, CYP2W1 was deemed as an interesting target in colorectal cancer therapy. This review sought to summarize the current understanding of the CYP2W1 biology and biochemistry, its genetic polymorphisms and cancer risk, and its implication as a tumor-specific diagnostic and therapeutic target.
Keywords: Cancer therapeutics, colorectal cancer, CYP2W1, cytochrome P450, prodrug
Current Cancer Drug Targets
Title:Cytochrome P450 2W1 (CYP2W1) in Colorectal Cancers
Volume: 16 Issue: 1
Author(s): Felicia Fei-Lei Chung, Chun Wai Mai, Pei Yuen Ng and Chee-Onn Leong
Affiliation:
Keywords: Cancer therapeutics, colorectal cancer, CYP2W1, cytochrome P450, prodrug
Abstract: Cytochrome P450, family 2, subfamily W, polypeptide 1 (CYP2W1) is a newly identified monooxygenase enzyme that is expressed specifically in tumor tissues and during fetal life. Particularly, high expression of CYP2W1 was observed in up to 60% of colorectal cancers and its expression correlated with poor survival. CYP2W1 has been shown to metabolize various endogenous substrates including lysophospholipids and several procarcinogens, such as polycyclic aromatic hydrocarbon. The specific substrate for CYP2W1, however, is currently unknown. Due to its tumor-specific expression and its unique catalytic activities in colorectal cancers, CYP2W1 was deemed as an interesting target in colorectal cancer therapy. This review sought to summarize the current understanding of the CYP2W1 biology and biochemistry, its genetic polymorphisms and cancer risk, and its implication as a tumor-specific diagnostic and therapeutic target.
Export Options
About this article
Cite this article as:
Fei-Lei Chung Felicia, Wai Mai Chun, Yuen Ng Pei and Leong Chee-Onn, Cytochrome P450 2W1 (CYP2W1) in Colorectal Cancers, Current Cancer Drug Targets 2016; 16 (1) . https://dx.doi.org/10.2174/1568009616888151112095948
DOI https://dx.doi.org/10.2174/1568009616888151112095948 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Advances in Anticancer Antibody-Drug Conjugates and Immunotoxins
Recent Patents on Anti-Cancer Drug Discovery Restoration of Antitumor Immunity Through Selective Inhibition of Myeloid Derived Suppressor Cells by Anticancer Therapies
Current Molecular Medicine Carbonic Anhydrase Related Protein VIII and its Role in Neurodegeneration and Cancer
Current Pharmaceutical Design MicroRNAs as Cancer Biomarkers
MicroRNA Rectal Cancer in Patients Younger than 40: Tumor Characteristics and Comparative Survival Based on a Single Institution
Current Cancer Therapy Reviews Recent Developments of Flavonoids with Various Activities
Current Topics in Medicinal Chemistry Novel Strategies and Model Studies for Colon Targeted Drug Delivery
Drug Delivery Letters Comparative DFT Study of 5-Fluorouracil Adsorption on Silica and Graphene for Bio-Medical Applications
Micro and Nanosystems Innovation in Contrast Agents for Magnetic Resonance Imaging
Current Medical Imaging On the Origin of Epidermal Cancers
Current Molecular Medicine Structural and Functional Diversity of Estrogen Receptor Ligands
Current Topics in Medicinal Chemistry The Epigenetic Modification of Epigallocatechin Gallate (EGCG) on Cancer
Current Drug Targets Recent Patents Concerning Modulators of Protein Kinase C
Recent Patents on DNA & Gene Sequences Three Decades of P-gp Inhibitors: Skimming Through Several Generations and Scaffolds
Current Medicinal Chemistry Condensed and Hydrolysable Tannins as Antioxidants Influencing the Health
Mini-Reviews in Medicinal Chemistry Dendrimers in Therapy for Breast and Colorectal Cancer
Current Medicinal Chemistry Cheminfomatic-based Drug Discovery of Human Tyrosine Kinase Inhibitors
Current Topics in Medicinal Chemistry Tumor Suppression by DNA Base Excision Repair
Mini-Reviews in Medicinal Chemistry Dual Targeting of Glioma U251 Cells with Nanoparticles Prevents Tumor Angiogenesis and Inhibits Tumor Growth
Current Neurovascular Research Targeted Enzyme Prodrug Therapies
Mini-Reviews in Medicinal Chemistry